CRISPR Therapeutics Stock
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform.
Sign up today and learn more about CRISPR Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About CRISPR Therapeutics Stock
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.
Funding History
| April 2014 | $25.0M |
|---|---|
| April 2015 | $64.0M |
| June 2016 | $38.0M |
Management
Scientific Founders
Daniel Anderson
Scientific Founders
Emmanuelle Charpentier
Founder & CFO
Shaun Foy
Founder & Chief Executive Officer
Rodger Novak
Scientific Founders
Craig Mello
Chief Scientific Officer
Bill Lundberg
Scientific Founders
Chad Cowan
Scientific Founders
Matthew Porteus
Press
Forbes - Nov, 19 2019
New Data From First Human Crispr Trials Shows Promising ResultsTechCrunch - Nov, 26 2018
Hospital in China denies links to world’s first gene-edited babiesTechCrunch - Nov, 25 2018
UPDATED: CRISPR scientist in China claims his team’s research has resulted in the world’s first gene-edited babiesNasdaq Place (press release) - Jun, 26 2018
Most Active Stock to Track: CRISPR Therapeutics AG (CRSP)StreetInsider.com - Jun, 16 2018
Form 4 CRISPR Therapeutics AG For: Jun 15 Filed by: Kulkarni SamarthSeeking Alpha - Jun, 11 2018
Crispr Therapeutics: Beware Of Articles Minimizing The Clinical Hold RiskXconomy - May, 30 2018
FDA Halts Plan for Vertex, CRISPR Therapeutics Sickle Cell StudyEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
